Download this datacard
Overview
Lobbying Costs
500,000€ - 599,999€
Financial year: Jul 2023 - Jun 2024
Lobbyists (Full time equivalent)
1.5 Fte (3)
Lobbyists with EP accreditation
2
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
CSL Behring
EU Transparency Register
030031840349-92 First registered on 17 Nov 2020
Goals / Remit
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. We have R&D and manufacturing sites across four continents, and specifically in Europe in Marburg, Germany and Bern, Switzerland.
Main EU files targeted
Pharmaceutical Strategy (including OMP legislation)
SoHO legislation
Industrial Strategy
European Health Union and Preparedness
Trade Strategy
Open Strategic Autonomy
Critical Medicines ActAddress
Head Office
1020 First Avenue
King of Prussia PA 19406-0901 USA
UNITED STATESEU Office
Bedrijvenlaan
Mechelen 28000
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 50% 3 Lobbyists (Full time equivalent)
1.5
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
2 accreditations were / are live (in bold) for the selected state of 05 Jan 2025
Name Start date End Date Ruediger Gatermann 06 Nov 2024 05 Nov 2025 irene de Cara Torres 25 Oct 2024 24 Oct 2025 Ms Joelle Khraiche 23 Mar 2024 26 Apr 2024 Mr Ruediger Gatermann 03 Feb 2024 26 Apr 2024 Ms Joelle Khraiche 16 Mar 2023 16 Mar 2024 Ms Irene de Cara Torres 14 Mar 2023 14 Mar 2024 Mr Ruediger Gatermann 18 Feb 2023 03 Feb 2024 Ms Irene de Cara Torres 15 Mar 2022 14 Mar 2023 Ms Joelle Khraiche 04 Mar 2022 04 Mar 2023 Mr Ruediger Gatermann 01 Mar 2022 18 Feb 2023 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Eucope - The European Confederation of Pharmaceutical Entrepreneurs
ARM - The Alliance for Regenerative Medicine
Europabio - The European Association for Bioindustries
EFPIA - The European Federation of Pharmaceutical Industries and AssociationsMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jul 2023 - Jun 2024
Lobbying costs for closed financial year
500,000€ - 599,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount dentons global advisors europe sa 50,000€ - 99,999€ harwood levitt consulting 200,000€ - 299,999€ Intermediaries for current year
Name harwood levitt consulting dentons global advisors europe sa Closed year Costs
500,000€ - 599,999€
Other financial info
Information under 14. covers our closed financial year between July 2022 and June 2023. This may lead to discrepancies in figures reported by our intermediaries whose financial year runs from January to December.
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
Economist Impact Cell & Gene Therapy Summit: on EU access to ATMPs (April 2023)
European Health Summit (June 2023) on resilience of health systems
World Orphan Drug Congress (Nov 2023) on clinical trials designs to support access to ATMPs in Europe
Publication of Company Response to the public consultation on the EU General Pharma Legislation (Nov 2023)Other activities
None declared
Meetings
Meetings
None declared